相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producingKlebsiella pneumoniaeof sequence type 39 during treatment
Irene Galani et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the bla KPC3 gene
E. Antinori et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Epidemiology of beta-Lactamase-Producing Pathogens
Karen Bush et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam
Claire Amaris Hobson et al.
SCIENTIFIC REPORTS (2020)
KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
Peera Hemarajata et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018
Kati Raisanen et al.
EUROSURVEILLANCE (2019)
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
Stephan Goettig et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Phenotypic, Biochemical, and Genetic Analysis of KPC-41, a KPC-3 Variant Conferring Resistance to Ceftazidime-Avibactam and Exhibiting Reduced Carbapenemase Activity
Linda Mueller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Patrice Nordmann et al.
CLINICAL INFECTIOUS DISEASES (2019)
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
Vasilios Athans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype
Mariana Castanheira et al.
MSPHERE (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
Melissa D. Barnes et al.
MBIO (2017)
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
Ryan K. Shields et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop
Marisa L. Winkler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
Henry Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Z. Aktas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase A MECHANISM FOR CEFTAZIDIME HYDROLYSIS
Peter S. Levitt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
分享论文
